
MicroTransponder
Total Raised
$190.25MInvestors Count
12Deal Terms
1Funding, Valuation & Revenue
16 Fundings
MicroTransponder has raised $190.25M over 16 rounds.
MicroTransponder's latest funding round was a Series F for $65M on March 12, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
3/12/2025 | Series F | $65M | U.S. Venture Partners, Action Potential Venture Capital, Exceller Hunt Ventures, Gilde Healthcare, Green Park & Golf Ventures, Longitude Capital, Osage University Partners, and The Vertical Group | 3 | ||
11/17/2023 | Biz Plan Competition | $0.2M | 1 | |||
6/6/2023 | Incubator/Accelerator | 1 | ||||
6/20/2022 | Series E | |||||
7/30/2021 | Debt - III |
Date | 3/12/2025 | 11/17/2023 | 6/6/2023 | 6/20/2022 | 7/30/2021 |
|---|---|---|---|---|---|
Round | Series F | Biz Plan Competition | Incubator/Accelerator | Series E | Debt - III |
Amount | $65M | $0.2M | |||
Investors | U.S. Venture Partners, Action Potential Venture Capital, Exceller Hunt Ventures, Gilde Healthcare, Green Park & Golf Ventures, Longitude Capital, Osage University Partners, and The Vertical Group | ||||
Valuation | |||||
Revenue | |||||
Sources | 3 | 1 | 1 |
MicroTransponder Deal Terms
1 Deal Term
MicroTransponder's deal structure is available for 1 funding round, including their Series B from June 12, 2012.
Round | Series B |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B |
MicroTransponder Investors
12 Investors
MicroTransponder has 12 investors. Green Park & Golf Ventures invested in MicroTransponder's Series F funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/29/2013 | 3/12/2025 | 4 Series B - II, Series C (2015), Series E (2022), Series F (2025) | Venture Capital | Texas | ||
6/20/2022 | 3/12/2025 | 2 Series E, Series F (2025) | Family Office | Texas | ||
6/20/2022 | 3/12/2025 | 2 Series E, Series F (2025) | Venture Capital | California | ||
Venture Capital | Pennsylvania | |||||
Venture Capital | New Jersey |
First funding | 8/29/2013 | 6/20/2022 | 6/20/2022 | ||
|---|---|---|---|---|---|
Last Funding | 3/12/2025 | 3/12/2025 | 3/12/2025 | ||
Investor | |||||
Rounds | 4 Series B - II, Series C (2015), Series E (2022), Series F (2025) | 2 Series E, Series F (2025) | 2 Series E, Series F (2025) | ||
Board Seats | |||||
Type | Venture Capital | Family Office | Venture Capital | Venture Capital | Venture Capital |
Location | Texas | Texas | California | Pennsylvania | New Jersey |
Compare MicroTransponder to Competitors
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
Spinal Restoration is involved in the development of therapies for chronic low back pain within the healthcare sector. The company's main offering is the Biostat4 System, a non-surgical procedure aimed at addressing chronic low back pain. Spinal Restoration serves the healthcare industry, with an emphasis on spinal health management. It was founded in 2004 and is based in Austin, Texas.
DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.

Endologix develops and manufactures minimally invasive treatments for vascular diseases in the medical device industry. The company offers endovascular stent grafts designed to treat abdominal aortic aneurysms (AAA) and provides solutions for aortic disorders. Endologix also provides virtual reality procedural training for physicians to enhance their skills in vascular interventions. It was founded in 1992 and is based in Irvine, California.
CryoPen is a company focused on advancing cryosurgical technology within the medical device industry. Its main offering is the CryoPen Surgical System, which employs linear compression cooling technology to perform cryosurgery using cryogenic gases or liquids. The system is designed for precision treatment of various skin lesions and pre-cancerous conditions, catering primarily to medical professionals in fields such as general practice, OB/GYN, podiatry, internal medicine, urology, and pediatrics. It was founded in 2005 and is based in Corpus Christi, Texas.
Disc Dynamics is an orthopedic spine company that provides surgical alternatives for degenerative disc disease. The company offers the DASCOR® Disc Arthroplasty System, which is a catheter-based technology designed to replace the nucleus of degenerated lumbar discs. This system is intended to relieve pain and restore function while preserving the anatomy of the spine. It was founded in 2000 and is based in Eden Prairie, Minnesota.
Loading...

